This report describes a modiˆed method for the quantitative determination of unbound micafungin (MCFG) in human plasma that is unrelated to chemical methods currently in use, and the relationship between the concentration of unbound and total MCFG in plasma of the patients. The mobile phase consisted of 50 mM phosphate buŠer:tetrahydrofuran (65:35, v/v). Samples were fractionated on a C-18 column. The ‰uorescence detection wavelengths of excitation and emission were set at 273 nm and 464 nm, respectively. The retention times of MCFG and 1-hydroxy-2-naphtoeic acid (internal standard: IS) were 10.5 min and 7.3 min, respectively. For each concentration of MCFG/IS, the peak height ratio on a 5-point calibration curve was linear from 0.004 to 0.08 mg/mL (r＝0.999, p＜0.001). In addition, the concentrations of unbound and total MCFG were measured in the plasma of 11 patients treated with MCFG for fungal infection. In total, 99 samples were collected. The concentration of unbound and total MCFG in plasma correlated with one another (r＝0.896, p＜0.001). These concentrations were not aŠected by serum albumin, total bilirubin, blood urea nitrogen, or creatinine clearance. There were small diŠerences of [fu (unbound MCFG/total MCFG)×100％] in the every term after start of treatment of MCFG. Further, there was no diŠerence in the unbound and total concentration of MCFG in plasma between the eŠective group and the ascertained eŠectiveness group. The concentration of MCFG in plasma could be used as an indicator of clinical eŠect as a substitute for the concentration of unbound MCFG in plasma.
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